Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims are pricing/cost related and are not supported by the provided KEYTRUDA label excerpt (Section 2/2.2), which contains only dosing/administration recommendations and treatment timing. Several claims assert pricing relationships (e.g., total price follows regimen; cost rises with duration) that are not addressed in the cited labeling.
Category Scores
Accurate Statements
Unsupported Statements
Keytruda’s listed wholesale price is based on the amount of drug used.
The provided label excerpt (2/2.2) contains no discussion of wholesale price or how it is calculated.
Keytruda dosing depends on dose and how it’s administered.
The excerpt specifies IV infusion administration and recommended dose levels/schedules, but does not support the claim phrased as dosing dependency on 'dose and how it’s administered' in the manner stated.
Keytruda is commonly dosed per body weight or body surface area for many patients.
The excerpt shows adult fixed doses (e.g., 200 mg q3 weeks or 400 mg q6 weeks) and pediatric mg/kg dosing; the claim is broader than what is supported by the excerpt.
Because the dose determines how many milligrams are used per treatment cycle, total cost typically changes with the prescribed dosage.
No cost/price relationship is described in the provided label excerpt.
In practice, the cost to a patient or payer varies with treatment duration because it’s given in cycles.
The excerpt provides treatment timing/duration (e.g., until progression or up to specified limits) but does not mention patient/payer cost.
Longer treatment means more cycles and more doses, so total drug spend rises with how long therapy continues.
The excerpt does not address drug spend or spending relationships.
The unit price for the drug does not typically change just because a patient receives more or fewer cycles.
The excerpt does not discuss unit pricing or how it changes with cycles.
With Keytruda, total price generally follows the regimen (dose per cycle × number of cycles).
The excerpt provides dosing regimens and treatment durations but provides no pricing formula or statements about total price.
Totals can differ due to factors like dose rounding and cycle scheduling.
The excerpt does not discuss dose rounding or how scheduling affects totals/pricing.
Contradictions
Important Omissions
No label-supported details were provided about dosing schedules relative to specific indications beyond generic claims; however, the user’s extracted claims focus on pricing rather than clinical dosing needs.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims concern pricing/cost mechanics rather than contraindications, boxed warnings, dosing modifications, monitoring, or administration safety. No safety-critical statements were made based on the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Pricing/wholesale price and total cost assertions are not supported by the provided FDA label excerpt (2/2.2), which contains dosing and administration recommendations only.
Suggested Improvement
Remove or revise cost/price statements to avoid implying label-supported pricing relationships; limit claims to what the label excerpt states (IV infusion; recommended doses and treatment timing/duration).